CN101724039A - Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof - Google Patents
Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof Download PDFInfo
- Publication number
- CN101724039A CN101724039A CN200810305136A CN200810305136A CN101724039A CN 101724039 A CN101724039 A CN 101724039A CN 200810305136 A CN200810305136 A CN 200810305136A CN 200810305136 A CN200810305136 A CN 200810305136A CN 101724039 A CN101724039 A CN 101724039A
- Authority
- CN
- China
- Prior art keywords
- sequence
- protein
- hel
- gly
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the biotechnology and the medical field and discloses a new human epididymal specific expression sperm binding protein HEL-38 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-38 protein and provides a recombinant expression vector which carries a DNA sequence used for encoding the protein. The protein is located at the main section region and the terminal segment region of the tail of a mature sperm, and the gene mainly has specific expression in an epididymis, indicated by RT-PCR. A band of about 35 KD is detected in the epididymis by using Western blot. The HEL-38 protein can be used as a target protein for developing an immunological contraceptive and clinically diagnosing and treating male infertility. A method for detecting a corresponding gene or protein based on development of the HEL-38 protein can be widely used for the research field of reproductive medicine.
Description
Technical field
The invention belongs to biotechnology and medical field.Specifically, the present invention relates to a kind of new human epididymal expression albumen HEL-38 and encoding gene and application
Background technology
This century, the mankind's development was faced with the problem of two sternnesses: on the one hand, global population is estimated will reach 9,000,000,000 in the year two thousand fifty in rapid expansion; On the other hand, according to World Health Organization's investigation, about 15% Mr. and Mrs exist sterile problem, and the sickness rate of developed country's infertility soared at nearest 10 years, and European developed country can be up to 30%, and wherein male factor accounts for half.World Health Organization's prediction, along with the increase of paathogenic factors such as environmental pollution and sexually transmitted disease (STD), in this century, infertility will become the third-largest disease that is only second to tumour and cardiovascular and cerebrovascular disease.But male sterility does not cause enough attention of society and medical circle, and the progress of therefore relevant male reproductive health is slow, lags significantly behind other subject.The effective ways that lack molecular biology aspect Clinics and Practices infertility.Because the sperm development obstacle can not natural fertilization, needs the doctor to obtain the offspring by being the tube baby.Utilize this kind technology to obtain the offspring, not only expended valuable time and fund, and have a lot of unhealthful latencies, the natural combination of smart ovum, the advantage in the normal growing process of having lost selected hereditary offspring's chance.Brought heavy spirit and economical load for family and society.
The sharp increase of whole world population has caused resource to exhaust and environmental degradation, becomes the serious threat of human health and existence.Our times population surpasses 6,000,000,000, estimates that according to the expert maximum population's capacity that Chinese resource environment can support is 15-16 hundred million.At present can be also very limited for the human contraceptives of selecting, also differ far away from the standard of " efficient, safe, reversible ".Develop safe and effective, the advanced practical new technology that avoids conception and control birth, product innovation, requiring with the personalization of the contraception medication of satisfying different crowd, different levels is the general trend of technical development of avoiding conception and controling birth both at home and abroad in recent years.
Epididymis is the vitals of spermioteleosis, and the sperm that testis produces need could obtain to move, be fertilized, defend and keep biological functions such as normal embryo development and defence by interacting with epididymis tube chamber microenvironment.Kind of secretory protein and sperm interaction surplus in the of nearly 200 participate in the spermioteleosis process, but people knows little about it to these proteic functions in the epididymis.The research of the epididymal proteins relevant with spermioteleosis will help to promote the progress of male genetic medical science, for the diagnosis of male infertility and treatment and development of new contraceptive provide the candidate molecular target, might bring new thinking and breakthrough to the male contraception of epididymis link simultaneously.
Summary of the invention
First purpose of the present invention provides a kind of new human epididymis expression sperm binding protein HEL-38.
A kind of human epididymal expression albumen HEL-38, it have the aminoacid sequence of sequence 2 in the sequence table or with the amino acid residue sequence of sequence 2 through replacement, disappearance or the interpolation of one or several amino-acid residue and have identical active by sequence 2 deutero-protein or polypeptide with the amino acid residue sequence of sequence 2.
People's epididymis secretory protein called after of the present invention: HEL-38 is made up of 335 amino-acid residues.HEL-38 albumen has 1 N glycosylation site, and 7 N-tetradecanoyl sites and 11 phosphorylation sites comprise 4 casein kinase i I phosphorylation sites and 7 protein kinase C phosphorylation sites.
Second purpose of the present invention provides the gene of coding human epididymis expression sperm binding protein HEL-38.It is one of following nucleotide sequences:
The dna sequence dna of sequence 1 in the sequence table, the GenBank number of registration is: EU668321;
The polynucleotide of SEQ ID No.2 protein sequence in the code sequence tabulation;
The dna sequence dna that limits with sequence in the sequence table 1 has 90% above homology, and coding identical function protein DNA sequence.
SEQ ID No.1 in the sequence table, full length cDNA sequence is 1310bp, is positioned on the people X karyomit(e), 335 amino acid of encoding, proteins encoded is HEL-38, does not contain signal peptide, its open reading frame is 1008bp, is a complete reading frame.
A third aspect of the present invention provides and has adopted the genetic engineering technique preparation to have the method for human epididymal expression albumen HEL-38 active polypeptide, and it comprises the carrier that contains above-mentioned polynucleotide sequence, and the host cell that is transformed or transduce by this carrier.
A fourth aspect of the present invention provides and above-mentioned human epididymis expression sperm binding protein HEL-38 specificity bonded antibody, and the auxiliary diagnosis of the infertility of developing thus that is used for the epididymal function caused by abnormal.
A fifth aspect of the present invention, the method that whether has human epididymis expression sperm binding protein HEL-38 in the sample that detects is provided, it comprises: with the specific antibody acting in conjunction under certain condition of testing sample and secretory protein, observe whether form immune complex, have immune complex to form just to point out and have secretory protein in the sample.
A sixth aspect of the present invention provides the purposes of albumen of the present invention and its encoding sequence.Albumen for example of the present invention can be used as the molecular target of diagnosis infertility, or be used for the treatment of infertility as the active drug composition, or as the target molecule of development of new contraceptive, or be used to screening and promote the active agonist of human epididymal expression albumen HEL-38, or be used to the active antagonist of screening inhibition human epididymal expression albumen HEL-38, or be used to the peptide finger print identification.Encoding sequence or its fragment according to human epididymal expression albumen HEL-38 can design primer or probe and be used for PCR or nucleic acid hybridization, perhaps are used to prepare gene chip.Albumen of the present invention also can be used for pharmaceutical composition, as the effective active composition, is used to produce a kind of medicine that resists diseases such as cause pathogeny imcrobe infection and tumour with this.
A seventh aspect of the present invention provides a kind of pharmaceutical composition, and described composition comprises albumen of the present invention, nucleotide sequence, construction or cell, and pharmaceutically acceptable carrier.
Albumen of the present invention can be expressed at the epididymis internal specific, is positioned the principal piece and the latter end zone of sperm tail, therefore may be relevant with motion.Because it is a kind of natural protein polypeptide, can predict and may have less side effect, other advantages of the present invention can be known from the following detailed description.
Description of drawings
The immunofluorescence location of Fig. 1 .HEL-38 albumen on people's sperm
Red fluorescence shows sperm nucleus; Green fluorescence shows the location of HEL-38 albumen on sperm;
The A group: positive control, A3 show that the HEL-75 protein binding is in whole sperm (article is delivered);
B group: negative control.
The C group: HEL-38 albumen location, C3. shows principal piece and the latter end zone of HEL-38 protein binding at sperm tail.
Scale: 5mm.
Fig. 2 HEL-38 gene organization expression map
1 caput epididymidis, 2 bodies of epididymis, 3 cauda epididymidiss, 4 testis, 5 hearts, 6 livers, 7 spleens, 8 kidneys, 9 stomaches, 10 negative controls
The western blot result that Fig. 3 .HEL-38 albumen is expressed at epididymal fluid
M:Marker; 1: positive control, HEL-75 albumen; 2: negative control, mice serum; 3:HEL-38 albumen
Albumen of the present invention has comprised the variant form of the same or similar inhibition biological active of having of described polypeptide or function, these variant forms comprise (but being not limited to): the amino acid sequence with respect to native protein has several (to be generally 1-50, preferably 1-30,1-20 more preferably, best 1-10) amino acid whose disappearance, insertion and replacement. In addition, described disappearance or insertion (increase) also can occur in the C end and/or the N end (has in 20 usually, preferably be in 10, more preferably be 5 with interior amino acid deletions or increase), in the art, when replacing with the close or similar amino acid of performance, usually can not change amino acid whose function, it is known in the art that the amino acid whose preservative replacement table of functional similarity is provided. Following 5 groups contain the mutually amino acid of conservative substitution separately; Aliphatic series: glycine (G), alanine (A), valine (V), leucine (L), isoleucine (I); Aromatics: phenylalanine (F), tyrosine (Y), tryptophan (W); Sulfur-bearing: methionine (M), cysteine (C); Alkalescence: arginine (R), lysine (K), histidine (H); Acid: aspartic acid (D), glutamine (Q). In addition, this term has also comprised fragment or the derivative of albumen, and condition is that this fragment or derivative have kept desirable protein biological activity.
Nucleotide sequence of the present invention can use pcr amplification method, recombination method or artificial synthetic method to obtain usually. For the pcr amplification method, can be disclosed according to the present invention relevant nucleotide sequence, especially open reading frame sequence designs primer, with the prepared cDNA library of conventional method well known by persons skilled in the art as template, amplification and must be about sequence. This normally is cloned into carrier with it, changes cell over to again, separates then obtaining relevant sequence from the host cell after the propagation by conventional method.
Among the present invention, use conventional method well known by persons skilled in the art to comprise to encode the nucleotide sequence of albumen of the present invention to be inserted in the carrier, these methods include but not limited to the extracorporeal recombinant DNA technology, recombinant technique etc. in the body.
Above-mentioned carrier can be used for transforming or transfection is suitable protokaryon and eukaryotic, so that it can express coded albumen of the present invention, host cell can be prokaryotic, such as bacterial cell, or the eukaryotic such as low, such as yeast cells; Or higher eucaryotic cells, such as insect cell etc. Adoptable conversion, transfection method include, but are not limited to: calcium phosphate precipitation, microinjection, electroporation, liposome-mediated etc.
Albumen of the present invention if need, can utilize its physics, chemical separating by the whole bag of tricks and the purifying expression product with other characteristics at cell inner expression, and these methods are well-known to those skilled in the art. The example of these methods includes but not limited to: conventional renaturation processes, process the combination of (salt analysis method), centrifugal, the broken bacterium of infiltration, the broken bacterium of sound wave, super centrifugal, sieve chromatography, adsorption chromatography, ion-exchange chromatography, high performance liquid chroma-tography and other various chromatographic techniques and these methods with conventional protein precipitant.
The present invention comprises that also albumen or its fragment are had specific polyclonal antibody and monoclonal antibody, also comprises having immunocompetent antibody fragment or chimeric antibody, as has mouse-anti body binding specificity but still keep antibody from people's antibody moiety.
Antibody of the present invention can be prepared by the known various technology of those skilled in that art. For example the gene outcome of recombinant antibodies, purifying or its have antigenic fragment, can be applied to animal to induce the generation of polyclonal antibody, and antibody of the present invention also can be monoclonal antibody. This type of monoclonal antibody can utilize hybridoma technology to prepare.
The inventor finds further that by research this protein localization is in principal piece and latter end zone (Fig. 1) of mature sperm afterbody, and RT-PCR result shows that this gene is mainly at epididymis specific expressed (Fig. 2). The inventor at expression in escherichia coli people HEL-38 albumen, use its immune mouse, obtained its polyvalent antibody. The inventor detects a 35KD left and right sides band (Fig. 3) with Western blot at the epididymis body.
Drug regimen of the present invention can be made various formulations according to various needs, usually pharmaceutical composition can be made injectable agent, for example liquid solution or suspension; Also can be made into before injection, be fit to allocate in solution or the suspension, the solid form of solution carrier, liposome is also included within the definition of pharmaceutically acceptable carrier, pharmaceutical composition of the present invention can by the doctor according to patient's kind, age, body weight and roughly the factor such as disease condition, administering mode determine the useful dosage of patient is used, in order to improve the medication effect, albumen of the present invention also can use jointly with other drug.
Below in conjunction with instantiation, further set forth the present invention, should understand these examples only is used for explanation the present invention and is not used in and limits the scope of the invention, unless description is arranged in addition, enforcement of the present invention will be adopted molecular biology, microbiology, recombinant DNA and immunologic routine techniques, and these all are known to those skilled in the art. These technology have complete description below in the document: Sambrook " molecular cloning experiment guide " second edition (1989) for example; " dna clone " I and II volume (D.N.Glover edits, 1985); " oligonucleotides is synthetic " (M.J.Gait edits, 1984); " nucleic acid hybridization " (B.D.Hames and S. J. Higgins edits. 1984); " protein purification; Principle and put into practice " the 2nd edition (Spring-Verlag, N.Y.), and " experiment immunization learn handbook I-IV volume (D.C.Weir and C.C.Blackwell edit 1986) or, can carry out according to the specification that the reagent manufacturer provides.
Embodiment
Gene clone and sequential analysis
The large scale sequencing screening is carried out in people's epididymis cDNA library that this laboratory makes up, obtained expressed sequence tag (EST), utilize the Unigene database to carry out electronic cloning, obtain people HEL-38 full-length cDNA.Use Expasy Translate tool (http://us.expasy.orghttp: //us.expasy.org), InterProScan (http://www.ebi.ac.uk/Tools/http: //www.ebi.ac.uk/Tools/) and Protein Stakes-of-wood roteinblast (http://www.ncbi.nlm.nih.gov/BLAST/http: //www.ncbi.nlm.nih.gov/BLAST/) wait prediction HEL-38 peptide sequence and supposition function.SignalP (http://www.cbs.dtu.dkhttp: //www.cbs.dtu.dk), location in PSORTII and WoLFPSORT software analysis such as (http://psort.nibb.ac.jp) this proteic signal peptide of prediction and the born of the same parents.ProfileScan (http://myhits.isb-sib.ch/cgi-bin/PFSCANhttp: //myhits.isb-sib.ch/cgi-bin/PFSCAN) prediction N holds glycosylation and phosphorylation site.
To the people HEL-38 full-length cDNA that obtains, gene order according to information biology predictive coding HEL-38 mature peptide designs a pair of special primer: F01:5 '-TTGGTACCGACGACGACGACAAG GGGAAGGTGAAGGTCGGA-3 ', F02:5 '-GCGGCGAATTC CTCCTTGGAGGCCAT-3 ', upstream and downstream primer two ends are introduced restriction endonuclease sites KpnI and EcoRI respectively.Primer is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.The people's epididymis cDNA library that makes up with this laboratory is a template, pcr amplification HEL-38 gene fragment.The PCR reaction conditions: 94 ℃ of pre-sex change 10min, (94 ℃, 40s; 55 ℃, 45s; 70 ℃, 30s) 30 circulations, 70 ℃ are extended 10min, 4 ℃ of preservations.After reaction finished, 1.0% agarose gel electrophoresis detected and Separation and Recovery purpose fragment, inserted the evaluation of checking order among the cloning vector pMD-18T.
Reorganization HEL-38 protein expression and purifying
Order-checking identifies that back HEL-38 gene is cloned among the expression vector pET-32b (+) by KpnI and EcoRI site, and it is consistent to make itself and fusion tag read frame.Recombinant expression vector pET32b (+)-HEL-38 changes E.coli BL21 (DE3) competent cell over to, utilize bacterium colony PCR screening positive clone, engineering strain is at 1mM IPTG, after inducing 4h under 32 ℃ of conditions, the recombinant protein that the N end has His-tag carries out separation and purification by " two step nickel affinity chromatography methods " to reorganization HEL-38 albumen.Briefly, " the first step affinity chromatography " is used for purification of Recombinant Trx-HEL-38 fusion rotein.Fusion rotein recombinant enterokinase cracking then discharges fusion tag.At last, reorganization HEL-38 albumen is reclaimed in utilization " the second step affinity chromatography ".Recombinant protein behind the purifying carries out quantitatively preserving with lyophilize then with Bradford (Bradford 1976) method.
The preparation of embodiment 2. anti-HEL-38 polyclonal antiserums
How anti-with the preparation of reorganization HEL-38 protein immunization BALB/C mice.Briefly, every mouse was injected the complete freund adjuvant (CFA) of 50 μ g recombinant proteins and equivalent in the 1st day.Injected incomplete freund adjuvant (IFA) booster immunization of 25 μ g recombinant proteins and equivalent then at the 15th, 30 and 45 day.Get blood from eyeball on the 60th day, and analyzed tiring and specificity of antibody with ELASA and western blot behind the separation of serum.Elisa assay shows that antibody titer reaches 1: 10000.Westernblot shows that the natural HEL-38 that extracts to recombinant protein with from people's epididymal fluid has good specificity.
The research of embodiment 3. people HEL-38mRNA distribution expression patterns
In order to determine the expression pattern of HEL-38, adopt sxemiquantitative RT-PCR to analyze the HEL-38 gene, testis, the heart, liver, spleen, lung, kidney, the differential expression in the tissue such as stomach at people's caput epididymidis, body, tail.With TRIzol (Tiangen, Beijing, China) extracted total RNA, the total RNA of 1ug 20UAMV reversed transcriptive enzyme (Promega) and 0.3ugoligod
T18 (Promega) reverse transcription becomes cDNA.Then, 2ul synthetic cDNA utilizes gene specific primer to carry out pcr amplification.The 20ul reaction system contains: 2ul 10 * PCR buffer (with MgCl
2), 2ul dNTP Mix (10mmol/L), each draws ul (25umol/L) 1ul, 1ul Taq archaeal dna polymerase (2.5U/ul), 2ulcDNA template and 11ulddH
2O.The program of PCR reaction is: 94 ℃, and 10min; 94 ℃, 1min; 54 ℃ of (to HEL-38)/49 ℃ (30s of β-actin); 72 ℃, 1min (35 circulation); 72 ℃ are extended 7min.The expression of β-actin is as confidential reference items.All pcr amplification products 1.5% agarose electrophoretic analysis.The result shows that this albumen is the epididymis specific expression protein.
Embodiment 4. people HEL-38 albumen are in the immunofluorescence location of tissue
Get people's testis, epididymis tissue freezing section, carry out immunofluorescence dyeing, wherein one anti-is mouse-anti rHEL-38 how anti-(1: 400), and two anti-ly are FITC-mark sheep anti-mouse igg (1: 200), and nucleus dyes with PI.Sections all after the dyeing are used Laser Scanning Confocal Microscope (Leica TCS SP2 AOBS) observations then with 80% glycerine mounting.Experiment is anti-as negative control with blood serum substituting before the mouse immune one simultaneously.
Embodiment 5. people's epididymal proteins extracts and Western blot
The total protein extract 20ug that will extract from people's epididymal fluid separates with 15%SDS-PAGE, and wet then forwarding to carried out western blot on the pvdf membrane.Mouse-anti people HEL-38 is how anti-to be one anti-(1: 5000), and two anti-ly are HRP-mark sheep anti-mouse igg (1: 500).The activity of horseradish peroxidase is analyzed Western blot with enhancement type HRP-DAB substrate colouring reagents box and is shown anti-people HEL-38 resists the natural HEL-38 that extracts to recombinant protein with from people's epididymal fluid to have good specificity more.
Embodiment 6. people HEL-38 albumen are in the immunofluorescence location of sperm
Collect and coat on the slide glass of 1% gelatin bag quilt after sperm washs with PBS, dry naturally, fix 10 minutes with methyl alcohol then.The slide glass that contains sperm at room temperature sealed 1 hour with 3%BSA, added mouse-anti rhBD32 then and resisted (1: 200) more, and 4 ℃ are spent the night.Mice serum is done negative control before the immunity.With PBST (PBS containing 0.1%Tween-20) washing three times, add corresponding FITC-mark sheep anti-mouse igg two anti-(1: 200).Slide glass is used 80% glycerine mounting then with PBST washing three times.With Olympus BX-52 microscopic examination, the HEL-38 protein binding may be relevant with the motion of sperm in the principal piece and the latter end zone of the sperm tail of sperm.
The anti-microbial activity of embodiment 7.HEL-38 recombinant protein
Utilization clone's colony-forming unit (CFU) is analyzed anti-microbial activity.Briefly, the E.coli XL-1blue of incubated overnight grows into 10mM PBS (pH 7.4) dilution of logarithmic phase (OD600=0.4-0.5) back.About 2 * 10
6The CFU/ml bacterium is mixing with the HEL-38 of 12.5~100ug/ml, 37 ℃ of cultivations.After beginning to cultivate 15,30,60and 120min is respectively in sampling.Sample is done serial dilution with 10mM PBS (pH 7.4), and each extent of dilution is got 100ul and is coated the LB agar plate, and 37 ℃ of overnight incubation are to forming single bacterium colony.Statistics bacterium colony number, anti-microbial activity represents that with the percentage ratio of bacteria living formula is: % survival=(albumen handle back survival clone number/handle clone's number of surviving in the back without albumen) * 100.
Experiment replaces albumen to handle bacterium as negative control with 10mM PBS (pH 7.4).
Embodiment 8 HEL-38 and sperm motility and relation research in vitro fertilization
Utilize HEL-38 to resist sealing normal people sperm more, carry out sperm motility and analysis in vitro fertilization then.Experiment is carried out according to the method that vitro life standard reagent box provides.Briefly, sperm uses SpermRinse-30 in 37 ℃, 5%CO earlier
2Cultivate capacitation in 1 hour.Added mouse-anti rHEL-38 according to 1: 200 then and resist more, in 37 ℃, 6%CO
2Cultivate and sealed in 2 hours.Sperm separated into two parts after the sealing, a part directly utilize computer aided system to analyze the mobility of sperm.Another part is with G-Fert washing 2 times, and to be adjusted to final concentration be 1.0 * 10
7Cells/ml.Add the 100ug sample of sperm in the culture dish of 35mm, cover paraffin oil then and put into 37 ℃, 6%CO
2With stand-by in the saturated humidity incubator.Handle the after ripening ovocyte through G-MOPS and add during preprepared fertilization drips, at 37 ℃, 6%CO
2Observe the fertilization situation with cultivating in the saturated humidity incubator, write down the fetal development situation every day.More than all the experiment use simultaneously the immunity before mice serum as negative control.
Sequence table
<110〉Li Jianyuan
<120〉human epididymal expression albumen HEL-38 and encoding gene thereof and application
<160>2
<170>PatentIn?version?3.5
<210>1
<211>1310
<212>DNA
<213>Homo?sapiens
<220>
<221>CDS
<222>(103)..(1110)
<400>1
aaattgagcc?cgcagcctcc?cgcttcgctc?tctgctcctc?ctgttcgaca?gtcagccgca 60
tcttcttttg?cgtcgccagc?cgagccacat?cgctcagaca?cc?atg?ggg?aag?gtg 114
Met?Gly?Lys?Val
1
aag?gtc?gga?gtc?aac?gga?ttt?ggt?cgt?att?ggg?cgc?ctg?gtc?acc?agg 162
Lys?Val?Gly?Val?Asn?Gly?Phe?Gly?Arg?Ile?Gly?Arg?Leu?Val?Thr?Arg
5 10 15 20
gct?gct?ttt?aac?tct?ggt?aaa?gtg?gat?att?gtt?gcc?atc?aat?gac?ccc 210
Ala?Ala?Phe?Asn?Ser?Gly?Lys?Val?Asp?Ile?Val?Ala?Ile?Asn?Asp?Pro
25 30 35
ttc?att?gac?ctc?aac?tac?atg?gtt?tac?atg?ttc?caa?tat?gat?tcc?acc 258
Phe?Ile?Asp?Leu?Asn?Tyr?Met?Val?Tyr?Met?Phe?Gln?Tyr?Asp?Ser?Thr
40 45 50
cat?ggc?aaa?ttc?cat?ggc?acc?gtc?aag?gct?gag?aac?ggg?aag?ctt?gtc 306
His?Gly?Lys?Phe?His?Gly?Thr?Val?Lys?Ala?Glu?Asn?Gly?Lys?Leu?Val
55 60 65
atc?aat?gga?aat?ccc?atc?acc?atc?ttc?cag?gag?cga?gat?ccc?tcc?aaa 354
Ile?Asn?Gly?Asn?Pro?Ile?Thr?Ile?Phe?Gln?Glu?Arg?Asp?Pro?Ser?Lys
70 75 80
atc?aag?tgg?ggc?gat?gct?ggc?gct?gag?tac?gtc?gtg?gag?tcc?act?ggc 402
Ile?Lys?Trp?Gly?Asp?Ala?Gly?Ala?Glu?Tyr?Val?Val?Glu?Ser?Thr?Gly
85 90 95 100
gtc?ttc?acc?acc?atg?gag?aag?gct?ggg?gct?cat?ttg?cag?ggg?gga?gcc 450
Val?Phe?Thr?Thr?Met?Glu?Lys?Ala?Gly?Ala?His?Leu?Gln?Gly?Gly?Ala
105 110 115
aaa?agg?gtc?atc?atc?tct?gcc?ccc?tct?gct?gat?gcc?ccc?atg?ttc?gtc 498
Lys?Arg?Val?Ile?Ile?Ser?Ala?Pro?Ser?Ala?Asp?Ala?Pro?Met?Phe?Val
120 125 130
atg?ggt?gtg?aac?cat?gag?aag?tat?gac?aac?agc?ctc?aag?atc?atc?agc 546
Met?Gly?Val?Asn?His?Glu?Lys?Tyr?Asp?Asn?Ser?Leu?Lys?Ile?Ile?Ser
135 140 145
aat?gcc?tcc?tgc?acc?acc?aac?tgc?tta?gca?ccc?ctg?gcc?aag?gtc?atc 594
Asn?Ala?Ser?Cys?Thr?Thr?Asn?Cys?Leu?Ala?Pro?Leu?Ala?Lys?Val?Ile
150 155 160
cat?gac?aac?ttt?ggt?atc?gtg?gaa?gga?ctc?atg?acc?aca?gtc?cat?gcc 642
His?Asp?Asn?Phe?Gly?Ile?Val?Glu?Gly?Leu?Met?Thr?Thr?Val?His?Ala
165 170 175 180
atc?act?gcc?acc?cag?aag?act?gtg?gat?ggc?ccc?tcc?ggg?aaa?ctg?tgg 690
Ile?Thr?Ala?Thr?Gln?Lys?Thr?Val?Asp?Gly?Pro?Ser?Gly?Lys?Leu?Trp
185 190 195
cgt?gat?ggc?cgc?ggg?gct?ctc?cag?aac?atc?atc?cct?gcc?tct?ac ggc 738
Arg?Asp?Gly?Arg?Gly?Ala?Leu?Gln?Asn?Ile?Ile?Pro?Ala?Ser?Thr?Gly
2002 05 210
gct?gcc?aag?gct?gtg?ggc?aag?gtc?atc?cct?gag?ctg?aac?ggg?aag?ctc 786
Ala?Ala?Lys?Ala?Val?Gly?Lys?Val?Ile?Pro?Glu?Leu?Asn?Gly?Lys?Leu
215 220 225
act?ggc?atg?gcc?ttc?cgt?gtc?ccc?act?gcc?aac?gtg?tca?gtg?gtg?gac 834
Thr?Gly?Met?Ala?Phe?Arg?Val?Pro?Thr?Ala?Asn?Val?Ser?Val?Val?Asp
230 235 240
ctg?acc?tgc?cgt?cta?gaa?aaa?cct?gcc?aaa?tat?gat?gac?atc?aag?aag 882
Leu?Thr?Cys?Arg?Leu?Glu?Lys?Pro?Ala?Lys?Tyr?Asp?Asp?Ile?Lys?Lys
245 250 255 260
gtg?gtg?aag?cag?gcg?tcg?gag?ggc?ccc?ctc?aag?ggc?atc?ctg?ggc?tac 930
Val?Val?Lys?Gln?Ala?Ser?Glu?Gly?Pro?Leu?Lys?Gly?Ile?Leu?Gly?Tyr
265 270 275
act?gag?cac?cag?gtg?gtc?tcc?tct?gac?ttc?aac?agc?gac?acc?cac?tcc 978
Thr?Glu?His?Gln?Val?Val?Ser?Ser?Asp?Phe?Asn?Ser?Asp?Thr?His?Ser
280 285 290
tcc?acc?ttt?gac?gct?ggg?gct?ggc?att?gcc?ctc?aac?gac?cac?ttt?gtc 1026
Ser?Thr?Phe?Asp?Ala?Gly?Ala?Gly?Ile?Ala?Leu?Asn?Asp?His?Phe?Val
295 300 305
aag?ctc?att?tcc?tgg?tat?gac?aac?gaa?ttt?ggc?tac?agc?aac?agg?gtg 1074
Lys?Leu?Ile?Ser?Trp?Tyr?Asp?Asn?Glu?Phe?Gly?Tyr?Ser?Asn?Arg?Val
310 315 320
gtg?gac?ctc?atg?gcc?cac?atg?gcc?tcc?aag?gag?taa?gacccctgga 1120
Val?Asp?Leu?Met?Ala?His?Met?Ala?Ser?Lys?Glu
325 330 335
ccaccagccc?cagcaagagc?acaagaggaa?gagagagacc?ctcactgctg?gggagtccct 1180
gccacactca?gtcccccacc?acactgaatc?tcccctcctc?acagttgcca?tgtagacccc 1240
ttgaagaggg?gaggggccta?gggagccgca?ccttgtcatg?taccatcaat?aaagtaccct 1300
gtgctcaacc 1310
<210>2
<211>335
<212>PRT
<213>Homo?sapiens
<400>2
Met?Gly?Lys?Val?Lys?Val?Gly?Val?Asn?Gly?Phe?Gly?Arg?Ile?Gly?Arg
1 5 10 15
Leu?Val?Thr?Arg?Ala?Ala?Phe?Asn?Ser?Gly?Lys?Val?Asp?Ile?Val?Ala
20 25 30
Ile?Asn?Asp?Pro?Phe?Ile?Asp?Leu?Asn?Tyr?Met?Val?Tyr?Met?Phe?Gln
35 40 45
Tyr?Asp?Ser?Thr?His?Gly?Lys?Phe?His?Gly?Thr?Val?Lys?Ala?Glu?Asn
50 55 60
Gly?Lys?Leu?Val?Ile?Asn?Gly?Asn?Pro?Ile?Thr?Ile?Phe?Gln?Glu?Arg
65 70 75 80
Asp?Pro?Ser?Lys?Ile?Lys?Trp?Gly?Asp?Ala?Gly?Ala?Glu?Tyr?Val?Val
85 90 95
Glu?Ser?Thr?Gly?Val?Phe?Thr?Thr?Met?Glu?Lys?Ala?Gly?Ala?His?Leu
100 105 110
Gln?Gly?Gly?Ala?Lys?Arg?Val?Ile?Ile?Ser?Ala?Pro?Ser?Ala?Asp?Ala
115 120 125
Pro?Met?Phe?Val?Met?Gly?Val?Asn?His?Glu?Lys?Tyr?Asp?Asn?Ser?Leu
130 135 140
Lys?Ile?Ile?Ser?Asn?Ala?Ser?Cys?Thr?Thr?Asn?Cys?Leu?Ala?Pro?Leu
145 150 155 160
Ala?Lys?Val?Ile?His?Asp?Asn?Phe?Gly?Ile?Val?Glu?Gly?Leu?Met?Thr
165 170 175
Thr?Val?His?Ala?Ile?Thr?Ala?Thr?Gln?Lys?Thr?Val?Asp?Gly?Pro?Ser
180 185 190
Gly?Lys?Leu?Trp?Arg?Asp?Gly?Arg?Gly?Ala?Leu?Gln?Asn?Ile?Ile?Pro
195 200 205
Ala?Ser?Thr?Gly?Ala?Ala?Lys?Ala?Val?Gly?Lys?Val?Ile?Pro?Glu?Leu
210 215 220
Asn?Gly?Lys?Leu?Thr?Gly?Met?Ala?Phe?Arg?Val?Pro?Thr?Ala?Asn?Val
225 230 235 240
Ser?Val?Val?Asp?Leu?Thr?Cys?Arg?Leu?Glu?Lys?Pro?Ala?Lys?Tyr?Asp
245 250 255
Asp?Ile?Lys?Lys?Val?Val?Lys?Gln?Ala?Ser?Glu?Gly?Pro?Leu?Lys?Gly
260 265 270
Ile?Leu?Gly?Tyr?Thr?Glu?His?Gln?Val?Val?Ser?Ser?Asp?Phe?Asn?Ser
275 280 285
Asp?Thr?His?Ser?Ser?Thr?Phe?Asp?Ala?Gly?Ala?Gly?Ile?Ala?Leu?Asn
290 295 300
Asp?His?Phe?Val?Lys?Leu?Ile?Ser?Trp?Tyr?Asp?Asn?Glu?Phe?Gly?Tyr
305 310 315 320
Ser?Asn?Arg?Val?Val?Asp?Leu?Met?Ala?His?Met?Ala?Ser?Lys?Glu
325 330 335
Claims (10)
1. human epididymis expression sperm binding protein HEL-38, it is characterized in that, it have the aminoacid sequence of sequence 2 in the sequence table or with the aminoacid sequence of sequence 2 through replacement, disappearance or the interpolation of one or several amino-acid residue and have with the identical active sequence 2 deutero-protein of amino acid residue sequence of sequence 2 with by chemical process synthetic protein.
2. the encoding gene of a human epididymis expression sperm binding protein HEL-38, it is one of following nucleotide sequences:
The nucleotide sequence of sequence 1 in the sequence table;
The dna sequence dna that limits with sequence in the sequence table 1 has 90% above homology, and the proteic dna sequence dna of coding identical function.
3. the eucaryon and the prokaryotic expression carrier that contain the described gene of claim 2.
4. the clone that contains the described gene of claim 2.
5. be the reagent of activeconstituents at the prepared various antibody of the described protein of claim 1 and with this antibody.
6. the pharmaceutical composition that provides at the described protein of claim 1, described composition comprises albumen of the present invention, nucleotide sequence, construction or cell, and pharmaceutically acceptable carrier.
7. the application of albumen according to claim 1 in the infertility diagnosis.
8. the application of albumen according to claim 1 in the infertility treatment.
9. the application of gene according to claim 2 in the new contraceptive of exploitation.
10. the application of albumen according to claim 1 in the new microbiotic of preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810305136A CN101724039A (en) | 2008-10-24 | 2008-10-24 | Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810305136A CN101724039A (en) | 2008-10-24 | 2008-10-24 | Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101724039A true CN101724039A (en) | 2010-06-09 |
Family
ID=42445652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810305136A Pending CN101724039A (en) | 2008-10-24 | 2008-10-24 | Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101724039A (en) |
-
2008
- 2008-10-24 CN CN200810305136A patent/CN101724039A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995013387A1 (en) | Tie-2, a novel receptor tyrosine kinase | |
JPH10513045A (en) | Novel chemokine expressed in human fetal spleen, its production and use | |
CN101724062A (en) | Human epididymis expression sperm binding protein HEL-172 as well as encoding gene and application thereof | |
CN101724058A (en) | Human epididymis expression sperm binding protein HEL-48, encoding gene and application thereof | |
CN101724033A (en) | Human epididymal expression sperm binding protein HEL-28 as well as encoding gene and application thereof | |
AU2003225440A1 (en) | Falp proteins | |
CN101724039A (en) | Human epididymal expression sperm binding protein HEL-38 as well as encoding gene and application thereof | |
EP1364963B1 (en) | A novel natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof | |
CN101724035A (en) | Human epididymal expression sperm binding protein HEL-43 as well as encoding gene and application thereof | |
CN101724036A (en) | Human epididymal expression sperm binding protein HEL-45 as well as encoding gene and application thereof | |
CN101724050A (en) | Human epididymal expression sperm binding protein HEL-214 as well as encoding gene and application thereof | |
CN101724065A (en) | Human epididymal expression sperm binding protein HEL-202 as well as encoding gene and application thereof | |
CN101724060A (en) | Human epididymis expression sperm binding protein HEL-90, encoding gene and application thereof | |
CN101724041A (en) | Human epididymal expression sperm binding protein HEL-47 as well as encoding gene and application thereof | |
CN101724043A (en) | Human epididymis expression sperm binding protein HEL-89, encoding gene and application thereof | |
CN101724063A (en) | Human epididymis expression sperm binding protein HEL-178 and encoding gene and application thereof | |
CN101724037A (en) | Human epididymis expression sperm binding protein HEL-6, encoding gene and application thereof | |
CN101724052A (en) | Human epididymis expression sperm binding protein HEL-65, encoding gene and application thereof | |
CN101724054A (en) | Human epididymal expression sperm binding protein HEL-213 as well as encoding gene and application thereof | |
CN101724048A (en) | Human epididymal expression sperm binding protein HEL-200 as well as encoding gene and application thereof | |
CN101724055A (en) | Human epididymal expression sperm binding protein HEL-215 as well as encoding gene and application thereof | |
CN101724045A (en) | Human epididymis expression sperm binding protein HEL-169 as well as encoding gene and application thereof | |
CN101724046A (en) | Human epididymis expression sperm binding protein HEL-18 and encoding gene and application thereof | |
CN101724044A (en) | Human epididymis expression sperm binding protein HEL-97, encoding gene and application thereof | |
CN101724049A (en) | Human epididymal expression sperm binding protein HEL-207 as well as encoding gene and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100609 |